Medtechs Ask: What’s The Big Deal For Us In Big Data?
This article was originally published in Start Up
Executive Summary
Medtech companies are still working out where they stand in the “win-win” that Big Data seems to provide. The European perspective was discussed at Eucomed 2014’s fall conference, the premier regional policy and regulatory forum for companies operating in EU markets.
You may also be interested in...
Digital Health Tools Ready For A Health Care System That Isn’t
Companies developing new digital health technologies say that the US health system needs to upgrade and start adopting tools that can track patients beyond hospital walls. Qualcomm Life aims to assist by merging data into information that health care providers can actually use.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.